A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma
2020-07-04
عنوان الدراسة
A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma
داعم الدراسة
Archigen Biotech Limited
دواء الدراسة
Rituximab/ SAIT101
رقم بروتوكول الدراسة
AGB 002
حالة الدراسة
Ongoing
موقع الدراسة
Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。